Phase 2 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a blood cancer called multiple myeloma, confirmed using standard medical guidelines
- You have previously been treated with three specific types of cancer drugs: a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody treatment
- Your multiple myeloma has been confirmed by your doctor to have gotten worse after your most recent treatment
- You are generally able to carry out basic daily activities (rated 0 or 1 on a standard activity scale), OR you have a score of 2 or 3 on this scale but only because of a stable physical condition unrelated to your myeloma or its treatment (for example, being in a wheelchair due to a previous spinal injury)
- You are willing and able to follow the lifestyle guidelines set out by the trial
Who may not be able to join:
- You have a serious known allergy or dangerous reaction to any of the medicines used in this trial or their ingredients
- You have had a stroke, mini-stroke, or seizure within the past 6 months
- You have experienced a serious heart or blood clot problem in the past 6 months, such as a heart attack, severe chest pain, a major blood clot (for example, in the lungs), a significant abnormal heart rhythm, or serious heart failure — though a straightforward clot in a leg vein alone is not automatically disqualifying (confirm with trial site)
- You have had major surgery or a serious injury within the past 2 weeks, have not fully recovered from surgery, or have major surgery planned during the time you would be in the trial or within 2 weeks after your last dose of the study treatment
- You have a significant problem with your sense of taste, or have certain conditions affecting your mouth or saliva glands, such as mouth sores, previous mouth cancer, severe gum disease, active mouth infections, or prior radiation treatment that left your mouth very dry (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Phone: 844-434-4210
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of Participants With Occurrence of Dysgeusia as Assessed by the Total Waterless Empirical Taste Test (WETT) Testing Score During the Prophylaxis Treatment Phase; Percentage of Participants With Occurrence of Severe Dysgeusia During the Prophylaxis Treatment Phase; Time to the First Onset of Severe Dysgeusia During the Prophylaxis Treatment Phase; Percentage of Participants Who Report Resolution/Improvement of Dysgeusia During the Prophylaxis Treatment Phase; Percentage of Participants Who Report Resolution/Improvement of Dysgeusia During the Prophylaxis Treatment Phase
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.